Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Long-Term Investments (2020 - 2025)

Historic Long-Term Investments for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $504.9 million.

  • Relay Therapeutics' Long-Term Investments fell 2653.83% to $504.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.9 million, marking a year-over-year decrease of 2653.83%. This contributed to the annual value of $657.0 million for FY2024, which is 835.92% up from last year.
  • As of Q3 2025, Relay Therapeutics' Long-Term Investments stood at $504.9 million, which was down 2653.83% from $542.8 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Long-Term Investments ranged from a high of $847.1 million in Q4 2022 and a low of $387.9 million during Q3 2021
  • In the last 5 years, Relay Therapeutics' Long-Term Investments had a median value of $657.0 million in 2024 and averaged $627.5 million.
  • As far as peak fluctuations go, Relay Therapeutics' Long-Term Investments surged by 19423.17% in 2021, and later tumbled by 2842.24% in 2023.
  • Relay Therapeutics' Long-Term Investments (Quarter) stood at $678.0 million in 2021, then rose by 24.95% to $847.1 million in 2022, then dropped by 28.42% to $606.4 million in 2023, then rose by 8.36% to $657.0 million in 2024, then fell by 23.16% to $504.9 million in 2025.
  • Its last three reported values are $504.9 million in Q3 2025, $542.8 million for Q2 2025, and $616.8 million during Q1 2025.